JP2021019589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021019589A5 JP2021019589A5 JP2020155809A JP2020155809A JP2021019589A5 JP 2021019589 A5 JP2021019589 A5 JP 2021019589A5 JP 2020155809 A JP2020155809 A JP 2020155809A JP 2020155809 A JP2020155809 A JP 2020155809A JP 2021019589 A5 JP2021019589 A5 JP 2021019589A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- isolated cell
- seq
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 31
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 7
- 229960001603 tamoxifen Drugs 0.000 claims 6
- 108091006106 transcriptional activators Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 108020001756 ligand binding domains Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 claims 1
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108700026226 TATA Box Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977751P | 2014-04-10 | 2014-04-10 | |
| US61/977,751 | 2014-04-10 | ||
| US201461986479P | 2014-04-30 | 2014-04-30 | |
| US61/986,479 | 2014-04-30 | ||
| US201462058973P | 2014-10-02 | 2014-10-02 | |
| US62/058,973 | 2014-10-02 | ||
| US201462088363P | 2014-12-05 | 2014-12-05 | |
| US62/088,363 | 2014-12-05 | ||
| US201462089730P | 2014-12-09 | 2014-12-09 | |
| US62/089,730 | 2014-12-09 | ||
| US201462090845P | 2014-12-11 | 2014-12-11 | |
| US62/090,845 | 2014-12-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561659A Division JP6765968B2 (ja) | 2014-04-10 | 2015-04-08 | 薬物制御による導入遺伝子の発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021019589A JP2021019589A (ja) | 2021-02-18 |
| JP2021019589A5 true JP2021019589A5 (enExample) | 2021-07-26 |
| JP7093385B2 JP7093385B2 (ja) | 2022-06-29 |
Family
ID=54288361
Family Applications (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561635A Active JP6765967B2 (ja) | 2014-04-10 | 2015-04-08 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2016561722A Active JP6772068B2 (ja) | 2014-04-10 | 2015-04-08 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2016561839A Pending JP2017515464A (ja) | 2014-04-10 | 2015-04-08 | 細胞免疫療法のための方法および組成物 |
| JP2017504604A Active JP6788573B6 (ja) | 2014-04-10 | 2015-04-08 | メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造 |
| JP2016561659A Active JP6765968B2 (ja) | 2014-04-10 | 2015-04-08 | 薬物制御による導入遺伝子の発現 |
| JP2020105133A Active JP7062720B2 (ja) | 2014-04-10 | 2020-06-18 | 細胞免疫療法のための方法および組成物 |
| JP2020155809A Active JP7093385B2 (ja) | 2014-04-10 | 2020-09-16 | 薬物制御による導入遺伝子の発現 |
| JP2020155429A Active JP7148580B2 (ja) | 2014-04-10 | 2020-09-16 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2020164326A Active JP7106610B2 (ja) | 2014-04-10 | 2020-09-30 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022069142A Active JP7542270B2 (ja) | 2014-04-10 | 2022-04-20 | 細胞免疫療法のための方法および組成物 |
| JP2022112278A Active JP7402933B2 (ja) | 2014-04-10 | 2022-07-13 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022150928A Active JP7508516B2 (ja) | 2014-04-10 | 2022-09-22 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561635A Active JP6765967B2 (ja) | 2014-04-10 | 2015-04-08 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2016561722A Active JP6772068B2 (ja) | 2014-04-10 | 2015-04-08 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2016561839A Pending JP2017515464A (ja) | 2014-04-10 | 2015-04-08 | 細胞免疫療法のための方法および組成物 |
| JP2017504604A Active JP6788573B6 (ja) | 2014-04-10 | 2015-04-08 | メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造 |
| JP2016561659A Active JP6765968B2 (ja) | 2014-04-10 | 2015-04-08 | 薬物制御による導入遺伝子の発現 |
| JP2020105133A Active JP7062720B2 (ja) | 2014-04-10 | 2020-06-18 | 細胞免疫療法のための方法および組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155429A Active JP7148580B2 (ja) | 2014-04-10 | 2020-09-16 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2020164326A Active JP7106610B2 (ja) | 2014-04-10 | 2020-09-30 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022069142A Active JP7542270B2 (ja) | 2014-04-10 | 2022-04-20 | 細胞免疫療法のための方法および組成物 |
| JP2022112278A Active JP7402933B2 (ja) | 2014-04-10 | 2022-07-13 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022150928A Active JP7508516B2 (ja) | 2014-04-10 | 2022-09-22 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (11) | US10865242B2 (enExample) |
| EP (8) | EP3129405B1 (enExample) |
| JP (12) | JP6765967B2 (enExample) |
| KR (8) | KR102463529B1 (enExample) |
| CN (7) | CN106573969B (enExample) |
| AU (8) | AU2015243920B2 (enExample) |
| BR (3) | BR112016023517A2 (enExample) |
| CA (4) | CA2945320A1 (enExample) |
| ES (2) | ES2880932T3 (enExample) |
| IL (5) | IL248243B2 (enExample) |
| MX (6) | MX2016013158A (enExample) |
| MY (4) | MY186846A (enExample) |
| NZ (3) | NZ725081A (enExample) |
| PH (4) | PH12016502009B1 (enExample) |
| RU (5) | RU2751920C2 (enExample) |
| SA (1) | SA516380056B1 (enExample) |
| SG (8) | SG11201608393TA (enExample) |
| WO (5) | WO2015157391A1 (enExample) |
| ZA (3) | ZA201607053B (enExample) |
Families Citing this family (202)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100548667C (zh) * | 2003-01-20 | 2009-10-14 | 日本瑞翁株式会社 | 层合件及其制造方法 |
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| MX373687B (es) * | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| KR102463529B1 (ko) | 2014-04-10 | 2022-11-07 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 약물 관련 트랜스진 발현 |
| CA2946312A1 (en) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| WO2015167766A1 (en) | 2014-04-29 | 2015-11-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies |
| IL293714A (en) | 2014-10-20 | 2022-08-01 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| CN107206024B (zh) | 2014-10-31 | 2021-12-03 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
| KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| KR20250067192A (ko) | 2014-12-03 | 2025-05-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 방법 및 조성물 |
| PL3226897T3 (pl) | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | Przeciwciała do celowania w antygen dojrzewania limfocytów b i sposoby ich zastosowania |
| HUE070137T2 (hu) | 2014-12-15 | 2025-05-28 | Univ California | CD19-re és CD20-ra érzékeny bispecifikus VAGY-kapu kiméra antigénreceptor |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| MX2017009254A (es) | 2015-01-16 | 2017-10-12 | Juno Therapeutics Inc | Anticuerpos y receptores de antigeno quimerico especificos para ror1. |
| WO2016138091A2 (en) * | 2015-02-24 | 2016-09-01 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified t cells |
| KR102632082B1 (ko) | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| JP6961490B2 (ja) * | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| CN115058395B (zh) | 2015-06-25 | 2025-07-18 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| WO2017222593A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| JP7162530B2 (ja) | 2015-08-07 | 2022-10-28 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| HK1256068A1 (zh) * | 2015-09-22 | 2019-09-13 | Julius-Maximilians-Universität Würzburg | 一种在淋巴细胞中高水平的和稳定的基因转移的方法 |
| CA3001230A1 (en) * | 2015-10-06 | 2017-04-13 | City Of Hope | Chimeric antigen receptors targeted to psca |
| CN108463228A (zh) * | 2015-10-23 | 2018-08-28 | 科罗拉多大学董事会法人团体 | 鳞状细胞癌的预后和治疗 |
| HK1254836A1 (zh) | 2015-10-30 | 2019-07-26 | Nbe-Therapeutics Ag | 抗-ror1抗体 |
| WO2017079703A1 (en) * | 2015-11-05 | 2017-05-11 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| PL3380620T3 (pl) * | 2015-11-23 | 2024-11-12 | Novartis Ag | Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie |
| CN108474005B (zh) * | 2015-12-14 | 2022-10-21 | 先驱生技股份有限公司 | 转位子系统、试剂盒及其用途 |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| RU2766190C2 (ru) | 2016-01-20 | 2022-02-09 | Дзе Скриппс Рисерч Инститьют | Композиции антител к ror1 и соответствующие способы |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| WO2017161212A1 (en) | 2016-03-16 | 2017-09-21 | Juno Therapeutics, Inc. | Methods for adaptive design of a treatment regimen and related treatments |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US12060394B2 (en) | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| CN109641012A (zh) | 2016-06-07 | 2019-04-16 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 与bcma结合的嵌合抗原受体和car-t细胞 |
| CA3025667A1 (en) * | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| US20190119636A1 (en) * | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| MA46649A (fr) | 2016-10-13 | 2019-08-21 | Juno Therapeutics Inc | Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane |
| WO2018075941A1 (en) * | 2016-10-21 | 2018-04-26 | Washington University | Ap4 and methods of promoting t cell activation |
| AU2017368248A1 (en) * | 2016-11-30 | 2019-06-06 | Intrexon Corporation | Steroid administration and immunotherapy |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| CN110291200B (zh) * | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| CN106800601B (zh) * | 2017-01-19 | 2021-04-06 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN110418802A (zh) * | 2017-01-20 | 2019-11-05 | 朱诺治疗学有限公司 | 细胞表面缀合物及相关的细胞组合物和方法 |
| ES2988795T3 (es) | 2017-02-27 | 2024-11-21 | Juno Therapeutics Inc | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| AU2018234640C9 (en) | 2017-03-14 | 2024-10-03 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
| CN106963945A (zh) * | 2017-03-27 | 2017-07-21 | 山东兴瑞生物科技有限公司 | 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗 |
| US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN108728477B (zh) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | 一种高效的转座突变系统及构建方法 |
| AU2018270156B2 (en) * | 2017-05-17 | 2023-04-20 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Generating mammalian T cell activation inducible synthetic promoters (syn+pro) to improve T cell therapy |
| WO2018218038A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| KR102460173B1 (ko) * | 2017-05-26 | 2022-10-31 | 주식회사 지씨셀 | 형질전환된 t세포를 이용한 자연살해세포의 배양방법 |
| WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| CN107335054B (zh) * | 2017-06-30 | 2021-01-15 | 山东兴瑞生物科技有限公司 | 一种慢性乙肝治疗性dc疫苗 |
| SG11202000846WA (en) | 2017-08-07 | 2020-02-27 | Nbe Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| EP3665277A4 (en) * | 2017-08-11 | 2021-05-12 | Tribiotica Llc | EPITOPIC GENERATION METHODS FOR BINDING TO RECOGNITION MOLECULES BY ASSEMBLY ON TEMPLATES |
| AU2018321134B2 (en) * | 2017-08-23 | 2025-06-26 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and CAR-T cells that bind CXCR5 |
| MX2020007357A (es) * | 2017-09-26 | 2021-08-11 | Longwood Univ | Reporte de antígeno quimérico específico de pd1 como una inmunoterapia. |
| CA3079264A1 (en) | 2017-10-18 | 2019-04-25 | Intrexon Corporation | Polypeptide compositions comprising spacers |
| CN107759700A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd19抗原的转基因t细胞及其制备方法与应用 |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| SG11202003688PA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Process for generating therapeutic compositions of engineered cells |
| CA3080395A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| CN120608077A (zh) | 2017-11-10 | 2025-09-09 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
| CN111655270A (zh) | 2017-11-14 | 2020-09-11 | 纪念斯隆-凯特琳癌症中心 | 分泌il-36的免疫应答细胞及其用途 |
| CA3084446A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019134036A1 (en) | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| CN110028588A (zh) * | 2018-01-11 | 2019-07-19 | 上海细胞治疗研究院 | 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用 |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| BR112020014913A2 (pt) | 2018-01-22 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Métodos para uso de células t car |
| CN108103027B (zh) * | 2018-02-02 | 2021-12-24 | 中国医学科学院血液病医院（血液学研究所） | 高效率血细胞重编程同时实现基因编辑的方法 |
| MY196582A (en) | 2018-02-13 | 2023-04-19 | Gilead Sciences Inc | PD-1/PD-L1 Inhibitors |
| CN108383914A (zh) * | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN111936617A (zh) * | 2018-03-16 | 2020-11-13 | 益缪索夫特公司 | 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| PE20210004A1 (es) | 2018-05-14 | 2021-01-05 | Gilead Sciences Inc | Inhibidores de mcl-1 |
| CA3100446A1 (en) * | 2018-05-15 | 2019-11-21 | Carsgen Therapeutics Co., Ltd. | Genetically engineered cell and application thereof |
| MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| US12497611B2 (en) | 2018-08-17 | 2025-12-16 | Yale University | Compositions and methods for high-throughput activation screening to boost T cell effector function |
| CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
| KR102839381B1 (ko) * | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US12173071B2 (en) | 2018-08-31 | 2024-12-24 | Seattle Children's Hospital | Methods and compositions comprising B7H3 chimeric antigen receptors |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| US20220242948A1 (en) * | 2018-10-19 | 2022-08-04 | Cartexell Inc. | Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| PL3873903T3 (pl) | 2018-10-31 | 2024-05-20 | Gilead Sciences, Inc. | Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| JP7179986B2 (ja) | 2018-11-14 | 2022-11-29 | グリーン クロス ラボ セル コーポレーション | 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 |
| KR20210104713A (ko) * | 2018-11-16 | 2021-08-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법 |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| EP3886894B1 (en) * | 2018-11-30 | 2024-03-13 | Juno Therapeutics, Inc. | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
| WO2020113194A2 (en) * | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| KR20210111244A (ko) * | 2018-11-30 | 2021-09-10 | 셀룰래리티 인코포레이티드 | 태반-유래 동종이계 car-t 세포 및 이의 용도 |
| CA3124103A1 (en) * | 2018-12-20 | 2020-06-25 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020191172A1 (en) * | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| US20200308248A1 (en) * | 2019-03-26 | 2020-10-01 | ST Phi Therapeutics | Chimeric Natural Killer Cell Receptors and Method of Using Thereof |
| EP3953383A4 (en) * | 2019-04-08 | 2023-01-18 | Russell Biotech, Inc. | Improved manufacturing procedures for cell based therapies |
| CN109994156A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含报告模板信息管理模块的精准用药智能报告系统 |
| CN109872792A (zh) * | 2019-04-16 | 2019-06-11 | 北京中佰耀因医药科技有限公司 | 一种用于指导精准用药的基因检测智能报告系统 |
| CN109994180A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含基因位点信息管理模块的精准用药智能报告系统 |
| CN109979545A (zh) * | 2019-04-16 | 2019-07-05 | 北京中佰耀因医药科技有限公司 | 一种含样本状态信息管理模块的精准用药智能报告系统 |
| CN110010200A (zh) * | 2019-04-16 | 2019-07-12 | 长沙三济生物科技有限公司 | 一种基因身份识别系统 |
| CN110010222A (zh) * | 2019-04-16 | 2019-07-12 | 长沙三济生物科技有限公司 | 一种基于精准用药知识库的基因身份识别系统 |
| CN109994176A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含样本类型信息管理模块的精准用药智能报告系统 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EP3980453A4 (en) * | 2019-06-07 | 2023-07-05 | The Trustees of the University of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| CN114269356A (zh) * | 2019-06-17 | 2022-04-01 | 伊诺奇安生物制药公司 | 诱导细胞免疫和体液免疫的基于同种异体t细胞的hiv疫苗 |
| WO2020254591A1 (en) * | 2019-06-19 | 2020-12-24 | Julius-Maximilians-Universität Würzburg | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| US20210009718A1 (en) | 2019-06-25 | 2021-01-14 | Gilead Sciences, Inc. | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE |
| CN110608991B (zh) * | 2019-09-09 | 2022-04-29 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN111533808B (zh) * | 2020-03-10 | 2021-02-09 | 南京医科大学 | 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用 |
| BR112022018491A2 (pt) | 2020-03-20 | 2022-11-29 | Lyell Immunopharma Inc | Marcadores de superfície celular recombinante |
| KR20230006891A (ko) | 2020-05-01 | 2023-01-11 | 길리애드 사이언시즈, 인코포레이티드 | Cd73를 억제하는 2,4-다이옥소피리미딘 화합물 |
| GB202007169D0 (en) * | 2020-05-14 | 2020-07-01 | Ospedale San Raffaele Srl | Epidermal growth factor receptor |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| KR20230021022A (ko) * | 2020-06-08 | 2023-02-13 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-cd171 키메라 항원 수용체 |
| US20230338422A1 (en) * | 2020-07-09 | 2023-10-26 | Nanjing Legend Biotech Co., Ltd. | Engineering gamma delta t cells with interleukin-36 for immunotherapy |
| JP2023535371A (ja) | 2020-07-17 | 2023-08-17 | シミュレックス インコーポレイテッド | 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法 |
| AU2021397206A1 (en) * | 2020-12-08 | 2023-07-27 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| US20240076351A1 (en) * | 2021-01-15 | 2024-03-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Hybrid and truncated immune cell proteins |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2023025208A1 (zh) * | 2021-08-24 | 2023-03-02 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| EP4416292A2 (en) | 2021-10-14 | 2024-08-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| EP4452415A1 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023173137A1 (en) * | 2022-03-11 | 2023-09-14 | Yale University | Compositions and methods for efficient and stable genetic modification of eukaryotic cells |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| EP4504243A1 (en) * | 2022-04-01 | 2025-02-12 | Miltenyi Biotec B.V. & Co. KG | A system for drug-inducible expression of a polynucleotide |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN114990069B (zh) * | 2022-05-17 | 2023-09-22 | 郑州大学第一附属医院 | 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用 |
| EP4532701A1 (en) * | 2022-05-27 | 2025-04-09 | Autolus Limited | Method |
| UY40304A (es) * | 2022-06-10 | 2023-12-29 | Biocad Joint Stock Co | Ácido nucleico con actividad promotora y uso del mismo |
| WO2024006702A1 (en) * | 2022-06-27 | 2024-01-04 | Foundation Medicine, Inc. | Methods and systems for predicting genotypic calls from whole-slide images |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| EP4633649A1 (en) * | 2022-12-15 | 2025-10-22 | The Board of Trustees of the Leland Stanford Junior University | Homology-independent targeted dna insertion in human t cells |
| WO2024137652A2 (en) * | 2022-12-20 | 2024-06-27 | Abata Therapeutics, Inc. | Cell therapies for type 1 diabetes |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| CN118359729A (zh) * | 2023-01-19 | 2024-07-19 | 武汉昭智生物技术有限公司 | 一种car分子、包含其的细胞或外泌体及它们的应用 |
| US20240290628A1 (en) * | 2023-02-24 | 2024-08-29 | American Air Liquide, Inc. | Etching method using oxygen-containing hydrofluorocarbon |
| US12257304B2 (en) | 2023-03-03 | 2025-03-25 | Arsenal Biosciences, Inc. | Systems targeting PSMA and CA9 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN116844685B (zh) * | 2023-07-03 | 2024-04-12 | 广州默锐医药科技有限公司 | 一种免疫治疗效果评估方法、装置、电子设备及存储介质 |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025207642A1 (en) * | 2024-03-25 | 2025-10-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Cxcr3 isoforms to improve recombinant receptor trafficking |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3150340B2 (ja) | 1990-11-13 | 2001-03-26 | イムネクス コーポレイション | 二機能選択可能融合遺伝子 |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| EP0650367A4 (en) | 1992-06-01 | 1998-04-15 | New England Medical Center Inc | BLOCKING OF INTERCELLULAR INTERACTIONS WITH CD43 CHEMICAL MOLECULES. |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| US6660257B1 (en) * | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US20040037816A1 (en) | 1999-04-15 | 2004-02-26 | Monash University | Graft acceptance through manipulation of thymic regeneration |
| US6912492B1 (en) * | 1999-05-25 | 2005-06-28 | University Of Medicine & Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
| JP4045713B2 (ja) | 2000-01-31 | 2008-02-13 | 松下電器産業株式会社 | 自動機用溶接機 |
| GB0015119D0 (en) * | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| AU7025201A (en) | 2000-07-03 | 2002-01-14 | Gala Design Inc | Expression vectors |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| RU2003129528A (ru) | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| EP2060582A1 (en) | 2001-05-31 | 2009-05-20 | Novartis Ag | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| WO2003025228A1 (en) * | 2001-09-18 | 2003-03-27 | Proteologics, Inc. | Methods and compositions for treating hcap associated diseases |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| PL375033A1 (en) | 2002-04-11 | 2005-11-14 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
| AU2003283995A1 (en) | 2002-09-30 | 2004-04-19 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| DK1594542T3 (da) * | 2003-02-20 | 2010-10-11 | Seattle Genetics Inc | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer |
| US20050129671A1 (en) * | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20060160090A1 (en) | 2003-04-11 | 2006-07-20 | Macina Robert A | Composition splice variants and methods relating to cancer specific genes and proteins |
| CN1809277A (zh) * | 2003-04-18 | 2006-07-26 | 诺伍德免疫学有限公司 | 先于胸腺再活化的移植物耐受 |
| WO2005017102A2 (en) * | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| CA2532460C (en) * | 2003-07-21 | 2012-04-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| CA2543329A1 (en) * | 2003-10-24 | 2005-05-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Orthogonal gene switches |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2005062881A2 (en) * | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) * | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| DE202005002921U1 (de) | 2005-02-23 | 2005-04-21 | Magcode Ag | Verbindungssystem, insbesondere elektrisches Verbindungssystem |
| US20070020237A1 (en) | 2005-06-01 | 2007-01-25 | Biotech Institute For International Innovation, Inc. | Glucose inducible insulin expression and methods of treating diabetes |
| KR20080090441A (ko) | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도 |
| WO2007137267A2 (en) | 2006-05-22 | 2007-11-29 | Hiprocell, Llc | Protein production using eukaryotic cell lines |
| US8148129B2 (en) | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
| WO2008012237A1 (en) * | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) * | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| CN101828113B (zh) | 2007-07-25 | 2014-04-16 | 德国弗劳恩霍夫协会债权安格万特学术研究所 | 自结合重组抗体融合蛋白 |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| DK2279253T3 (en) * | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| CN105274125A (zh) | 2008-09-26 | 2016-01-27 | 托卡根公司 | 基因治疗载体和胞嘧啶脱氨酶 |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| EP2438443A4 (en) | 2009-06-02 | 2012-07-25 | Targeted Molecular Diagnostics Llc | METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2) |
| US9873035B2 (en) * | 2009-07-09 | 2018-01-23 | Cfph, Llc | Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| AU2010301042B2 (en) | 2009-10-01 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| DK2496698T3 (en) * | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3179835A1 (en) | 2011-01-18 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| NZ743310A (en) * | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| JP2014514927A (ja) * | 2011-04-13 | 2014-06-26 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| ES2773891T3 (es) | 2011-06-01 | 2020-07-15 | Prec Biosciences Inc | Procedimientos para la producción de líneas celulares de mamífero modificadas con transgenes amplificados |
| AU2012274127B2 (en) * | 2011-06-22 | 2017-06-22 | F. Hoffmann-La Roche Ag | Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes |
| RU2644243C2 (ru) | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы к cd22 |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| ITRM20120058A1 (it) * | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| JP2015509717A (ja) * | 2012-02-22 | 2015-04-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用 |
| KR102086874B1 (ko) | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| AU2013267350A1 (en) | 2012-05-30 | 2015-01-29 | Baylor College Of Medicine | Supercoiled MiniVectors as a tool for DNA repair, alteration and replacement |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| WO2013180287A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電気株式会社 | スイッチングシステム、ラインカード、スイッチカード、ｆｄｂ学習方法、ｆｄｂ学習調停方法及びプログラム |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| WO2014039044A1 (en) * | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| US20160017048A1 (en) * | 2013-03-07 | 2016-01-21 | Baylor College Of Medicine | Targeting cd138 in cancer |
| EP2777711A1 (en) * | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| SG11201509609SA (en) | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| AU2014342020C1 (en) | 2013-10-31 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof |
| MX373687B (es) | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| US10137170B2 (en) | 2013-12-20 | 2018-11-27 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides |
| CA2934436A1 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| ES2767423T3 (es) | 2014-01-13 | 2020-06-17 | Hope City | Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso |
| EP3094649A1 (en) | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn-binding properties |
| KR102375998B1 (ko) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 항원 수용체 및 제조방법 |
| ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| KR102463529B1 (ko) | 2014-04-10 | 2022-11-07 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 약물 관련 트랜스진 발현 |
| US10604740B2 (en) | 2014-05-14 | 2020-03-31 | Carsgen Therapeutics Limited | Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein |
| KR20240093757A (ko) | 2014-06-02 | 2024-06-24 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Cd19를 표적화하는 키메라 항원 수용체 |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| BR112017008710A8 (pt) | 2014-10-27 | 2023-04-25 | Hutchinson Fred Cancer Res | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| EP4424326A3 (en) | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| CA2989347A1 (en) | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| JP7162530B2 (ja) | 2015-08-07 | 2022-10-28 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| KR20180105709A (ko) | 2016-02-05 | 2018-09-28 | 시티 오브 호프 | 중추 신경계의 암의 치료를 위한 조작된 t 세포의 투여 |
| WO2017172952A1 (en) | 2016-04-01 | 2017-10-05 | Promab Biotechnologies, Inc. | Flag tagged cd19-car-t cells |
| TWI695010B (zh) | 2016-09-28 | 2020-06-01 | 美商凱特製藥公司 | 抗原結合分子類和使用彼等之方法 |
| EP3757120B8 (en) | 2016-10-04 | 2022-06-15 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| KR20210074274A (ko) | 2018-08-06 | 2021-06-21 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물 |
| US10714296B2 (en) | 2018-12-12 | 2020-07-14 | Axcelis Technologies, Inc. | Ion source with tailored extraction shape |
| US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2015
- 2015-04-08 KR KR1020167031064A patent/KR102463529B1/ko active Active
- 2015-04-08 BR BR112016023517A patent/BR112016023517A2/pt not_active Application Discontinuation
- 2015-04-08 CA CA2945320A patent/CA2945320A1/en active Pending
- 2015-04-08 KR KR1020167031070A patent/KR102509481B1/ko active Active
- 2015-04-08 MX MX2016013158A patent/MX2016013158A/es unknown
- 2015-04-08 SG SG11201608393TA patent/SG11201608393TA/en unknown
- 2015-04-08 CN CN201580027077.0A patent/CN106573969B/zh active Active
- 2015-04-08 AU AU2015243920A patent/AU2015243920B2/en not_active Ceased
- 2015-04-08 SG SG10201808825XA patent/SG10201808825XA/en unknown
- 2015-04-08 ES ES15777065T patent/ES2880932T3/es active Active
- 2015-04-08 BR BR112016023500-2A patent/BR112016023500B1/pt active IP Right Grant
- 2015-04-08 MY MYPI2016703720A patent/MY186846A/en unknown
- 2015-04-08 CN CN201580030056.4A patent/CN106574246A/zh active Pending
- 2015-04-08 AU AU2015243882A patent/AU2015243882C1/en not_active Ceased
- 2015-04-08 EP EP15776745.0A patent/EP3129405B1/en active Active
- 2015-04-08 MX MX2016013144A patent/MX395574B/es unknown
- 2015-04-08 AU AU2015243927A patent/AU2015243927B2/en not_active Ceased
- 2015-04-08 MX MX2016013160A patent/MX387465B/es unknown
- 2015-04-08 WO PCT/US2015/024882 patent/WO2015157391A1/en not_active Ceased
- 2015-04-08 CN CN201580030815.7A patent/CN106661570B/zh active Active
- 2015-04-08 RU RU2016143388A patent/RU2751920C2/ru active
- 2015-04-08 EP EP15776211.3A patent/EP3129053A4/en not_active Withdrawn
- 2015-04-08 EP EP15776501.7A patent/EP3129480A4/en active Pending
- 2015-04-08 PH PH1/2016/502009A patent/PH12016502009B1/en unknown
- 2015-04-08 NZ NZ725081A patent/NZ725081A/en not_active IP Right Cessation
- 2015-04-08 CA CA2945303A patent/CA2945303C/en active Active
- 2015-04-08 PH PH1/2016/502010A patent/PH12016502010B1/en unknown
- 2015-04-08 JP JP2016561635A patent/JP6765967B2/ja active Active
- 2015-04-08 NZ NZ73944815A patent/NZ739448A/en not_active IP Right Cessation
- 2015-04-08 WO PCT/US2015/024895 patent/WO2015157399A1/en not_active Ceased
- 2015-04-08 EP EP21180797.9A patent/EP3954708A1/en active Pending
- 2015-04-08 MY MYPI2016703722A patent/MY192522A/en unknown
- 2015-04-08 SG SG10201808811QA patent/SG10201808811QA/en unknown
- 2015-04-08 EP EP15777020.7A patent/EP3129471A4/en active Pending
- 2015-04-08 BR BR112016023523A patent/BR112016023523A2/pt not_active Application Discontinuation
- 2015-04-08 SG SG10201808819XA patent/SG10201808819XA/en unknown
- 2015-04-08 JP JP2016561722A patent/JP6772068B2/ja active Active
- 2015-04-08 JP JP2016561839A patent/JP2017515464A/ja active Pending
- 2015-04-08 RU RU2016143385A patent/RU2751921C2/ru active
- 2015-04-08 US US15/302,403 patent/US10865242B2/en active Active
- 2015-04-08 CN CN201580030814.2A patent/CN106536558A/zh active Pending
- 2015-04-08 MY MYPI2016703721A patent/MY184163A/en unknown
- 2015-04-08 IL IL248243A patent/IL248243B2/en unknown
- 2015-04-08 CA CA2945308A patent/CA2945308C/en active Active
- 2015-04-08 AU AU2015243922A patent/AU2015243922B2/en active Active
- 2015-04-08 KR KR1020227038237A patent/KR102618955B1/ko active Active
- 2015-04-08 JP JP2017504604A patent/JP6788573B6/ja active Active
- 2015-04-08 JP JP2016561659A patent/JP6765968B2/ja active Active
- 2015-04-08 CN CN201580029752.3A patent/CN106535934A/zh active Pending
- 2015-04-08 WO PCT/US2015/024947 patent/WO2015157432A1/en not_active Ceased
- 2015-04-08 EP EP15777065.2A patent/EP3129399B1/en active Active
- 2015-04-08 US US15/302,415 patent/US10266592B2/en active Active
- 2015-04-08 SG SG11201608396YA patent/SG11201608396YA/en unknown
- 2015-04-08 ES ES15776745T patent/ES2867224T3/es active Active
- 2015-04-08 IL IL297591A patent/IL297591B2/en unknown
- 2015-04-08 AU AU2015243849A patent/AU2015243849B2/en not_active Ceased
- 2015-04-08 KR KR1020167031068A patent/KR102387243B1/ko active Active
- 2015-04-08 KR KR1020237007831A patent/KR102730216B1/ko active Active
- 2015-04-08 US US15/302,426 patent/US20170015746A1/en not_active Abandoned
- 2015-04-08 CN CN202110101875.0A patent/CN112877291A/zh active Pending
- 2015-04-08 US US15/302,420 patent/US10611837B2/en active Active
- 2015-04-08 CN CN202110842538.7A patent/CN113528581A/zh active Pending
- 2015-04-08 RU RU2016143389A patent/RU2016143389A/ru not_active Application Discontinuation
- 2015-04-08 EP EP22151326.0A patent/EP4056201A1/en active Pending
- 2015-04-08 KR KR1020167031069A patent/KR20160144431A/ko not_active Abandoned
- 2015-04-08 SG SG10201808833XA patent/SG10201808833XA/en unknown
- 2015-04-08 WO PCT/US2015/024866 patent/WO2015157384A1/en not_active Ceased
- 2015-04-08 NZ NZ725079A patent/NZ725079A/en not_active IP Right Cessation
- 2015-04-08 WO PCT/US2015/024868 patent/WO2015157386A1/en not_active Ceased
- 2015-04-08 CA CA2945305A patent/CA2945305C/en active Active
- 2015-04-08 KR KR1020227011931A patent/KR102600544B1/ko active Active
- 2015-04-08 US US15/302,449 patent/US20170029774A1/en not_active Abandoned
- 2015-04-08 IL IL248238A patent/IL248238B2/en unknown
- 2015-04-08 SG SG11201608395PA patent/SG11201608395PA/en unknown
- 2015-04-08 SG SG11201608392WA patent/SG11201608392WA/en unknown
- 2015-04-08 PH PH1/2016/502011A patent/PH12016502011B1/en unknown
- 2015-04-08 KR KR1020167031067A patent/KR102508166B1/ko active Active
- 2015-04-08 EP EP21175647.3A patent/EP3943507A1/en active Pending
- 2015-04-08 MX MX2016013159A patent/MX389797B/es unknown
- 2015-04-08 MX MX2016013149A patent/MX2016013149A/es unknown
- 2015-04-08 RU RU2016143384A patent/RU2729112C2/ru active
- 2015-04-08 MY MYPI2016703719A patent/MY185678A/en unknown
- 2015-04-08 RU RU2016143381A patent/RU2752275C2/ru active
-
2016
- 2016-10-06 MX MX2022010807A patent/MX2022010807A/es unknown
- 2016-10-06 IL IL248235A patent/IL248235B/en active IP Right Grant
- 2016-10-06 IL IL248229A patent/IL248229B2/en unknown
- 2016-10-10 SA SA516380056A patent/SA516380056B1/ar unknown
- 2016-10-10 PH PH12016502012A patent/PH12016502012A1/en unknown
- 2016-10-13 ZA ZA2016/07053A patent/ZA201607053B/en unknown
- 2016-10-13 ZA ZA2016/07060A patent/ZA201607060B/en unknown
- 2016-10-13 ZA ZA2016/07061A patent/ZA201607061B/en unknown
-
2019
- 2019-02-27 US US16/287,074 patent/US11155616B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/794,673 patent/US11414486B2/en active Active
- 2020-06-18 JP JP2020105133A patent/JP7062720B2/ja active Active
- 2020-09-16 JP JP2020155809A patent/JP7093385B2/ja active Active
- 2020-09-16 JP JP2020155429A patent/JP7148580B2/ja active Active
- 2020-09-30 JP JP2020164326A patent/JP7106610B2/ja active Active
- 2020-11-12 US US17/096,138 patent/US12258397B2/en active Active
- 2020-11-13 US US17/097,630 patent/US20210371517A1/en active Pending
-
2021
- 2021-01-04 AU AU2021200007A patent/AU2021200007B2/en not_active Ceased
- 2021-03-17 AU AU2021201679A patent/AU2021201679B2/en not_active Ceased
- 2021-09-10 US US17/472,284 patent/US12202897B2/en active Active
- 2021-11-26 AU AU2021273652A patent/AU2021273652A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069142A patent/JP7542270B2/ja active Active
- 2022-07-13 JP JP2022112278A patent/JP7402933B2/ja active Active
- 2022-07-15 US US17/812,848 patent/US12448445B2/en active Active
- 2022-09-22 JP JP2022150928A patent/JP7508516B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021019589A5 (enExample) | ||
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| US10766943B2 (en) | Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| Sun et al. | Construction and evaluation of a novel humanized HER2-specific chimeric receptor | |
| Han et al. | Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges | |
| KR102308597B1 (ko) | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 | |
| Krebs et al. | T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1 | |
| CN104822705B (zh) | M971嵌合抗原受体 | |
| FI3824905T3 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2018523485A5 (enExample) | ||
| JP2019500894A5 (enExample) | ||
| JP2016534717A5 (enExample) | ||
| JP2017513470A5 (enExample) | ||
| Shi et al. | Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects | |
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP2016520074A5 (enExample) | ||
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017537627A5 (enExample) | ||
| WO2017192536A1 (en) | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy | |
| JPWO2020051493A5 (enExample) | ||
| Li et al. | Genetically modified T-cells affinity to tumor cells-development of adoptive T-cell immunotherapy | |
| Hull et al. | Novel approaches to promote CAR T-cell function in solid tumors | |
| Krebs et al. | T cells redirected to IL13Rα2 with IL13 mutein-CARs have antiglioma activity but also recognize IL13Rα1 | |
| HK40068149A (en) | Universal chimeric antigen receptor expressing immune cells and method of manufacturing the same and the therapeutic use of the same | |
| KR20210066743A (ko) | CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |